Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

• Status: Recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

This study plans to learn more about the effects of levetiracetam (LEV) on brain activity and cognition in schizophrenia and schizoaffective disorder. Levetiracetam is an anti-seizure drug, also called an anticonvulsant.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: VA Office of Research and Development
• Treatments: Etiracetam; Levetiracetam; Piracetam

Criteria

Inclusion Criteria:

• Diagnosis of schizophrenia or schizoaffective disorder

• Good general health

• Normal vital signs (blood pressure, pulse, respiration)

Exclusion Criteria:

• Substance abuse

• Significant neurological disorders

• Significant head trauma/injury

• Pregnancy

• MRI-specific exclusion criteria, e.g.,:

• claustrophobia

• weight>400 lbs

• metal in the body